Rozina lagăru *, Monica Luminos **, Ch. Jugulete ***
* Rozina Iagăru – Medic primar boli infecțioase, Șef de secție Institutul de Boli Infecțioase “Prof. dr. Matei Balș”
** Monica Luminos – Medic primar boli infecțioase, Șef de secție Institutul de Boli Infecțioase “Prof. dr. Matei Balș” șef de lucrări U.M.F – “Carol Davila”, București
*** Ch. Jugulete – Medic specialist boli infecțioase, Asistent Universitar U.M.F “Carol Davila” București
Abstract
This article is a review of the known data concerning linezolid in children. Linezolid, the first member of the oxazolidinones class of antibiotics licensed, by handing to the 50 S ribosomal sub unit. It is approved for use in adults and children for serious infections caused by Enterococcus faecium or Enterococcus faecalis, including vancomycin – resistant strains (VRE), Staphilococcus aureus including methicillin – resistant strains (MRSA), coagulase – negative staphilococci and streptococci including penicillin – resistant Streptococcus pneumoniae. This review focuses on antimicrobial activity, pharma cokinetics and clinical uses of linezolid.